SAB Biotherapeutics Secures $95M Funding: Impact on Biotech ETF Liquidity

SAB Biotherapeutics has officially announced the successful raising of $95 million in a new funding round, a move that signals renewed institutional investor confidence in the clinical-stage biotechnology sector. This capital injection is strategically vital for the company, as it provides the financial runway necessary to reach its next operational milestones without the immediate pressure of further fundraising. According to company statements, crucial clinical trial data…